抗ANGPT2抗体与急性髓系白血病的研究进展  

Research Advances on Anti-ANGPT2 Antibody in Acute Myeloid Leukemia——Review

作　　者：陈砚伟 杨红[1] 牟红[1] 杨松兰[1] 张铀[1] 

机构地区：[1]昆明医科大学第二附属医院血液科,云南昆明650500

出　　处：《中国实验血液学杂志》2014年第5期1459-1462,共4页Journal of Experimental Hematology

基　　金：云南省科技厅联合专项(2011C115)

摘　　要：血管生成素2(angiopoietin,ANGPT2)在肿瘤血管形成中扮演着重要的角色。ANGPT2拮抗ANGPT1对血管的稳定作用有影响,从而促进了肿瘤生长、侵袭,肿瘤细胞增生,继而影响肿瘤血管的密度。为此,许多学者针对ANGPT2的抗肿瘤治疗展开了研究,目前已取得了一定的进展。本文就ANGPT2在急性髓系白血病(AML)发病机制中的重要作用,诸如对白血病患者骨髓新生和血管增生的作用、以及侵袭和转移等问题进行简要的概括和阐述,以便为靶向ANGPT2的治疗提供依据。Angiopoietin2 （ ANGPT2 ） plays an important role in tumor angiopoiesis. ANGPT2 antagonises ANGPT1 resulting in an effect on the stability of blood vessels, which promotes tumor growth, invasion, proliferation as well as relating to tumor vascular density. A lot of researches published papers about anti-ANGPT2 for the treatment of tumor, and have made some progresses. In this review, the role of ANGPT2 in the pathogenesis of acute myelogenous leukemia （AML）, including its effects on proliferation of leukemia cells, bone marrow angiopoiesis, tumor invasion and metastasis are briefly summarised in order to provide the basis for targeted ANGPT2 in treatment of AML.

关 键 词：血管生成素2 抗血管生成素 急性髓细胞白血病 

分 类 号：R733.71[医药卫生—肿瘤]